STAAR Surgical (STAA) Tops Q1 EPS by 5c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
May 13, 2026 4:01 PM EDTNet Sales of $93.5 million, highest first quarter Net Sales in Companys history, up 119.6% Y/Y
Net Income of $5.2 million, with GAAP EPS of $0.10
Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share
Earnings Call and Webcast Today at 5:30 PM Eastern
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL) for vision correction, today reported results for the first quarter... More
